Overview

Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Status:
Terminated
Trial end date:
2018-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the safety and efficacy of ofatumumab added to chlorambucil in patients with untreated Chronic Lymphocytic Leukemia.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Novartis Pharmaceuticals
Treatments:
Antibodies, Monoclonal
Chlorambucil
Ofatumumab